Abstract
Background and Aims: Pulmonary hypertension (PH) is a chronic progressing vascular disease characterized by pulmonary arteriole remodeling and loss of pulmonary microvasculature. The aim of this study was to investigate a potential role for the miR-495 in PH pathogenesis and to explore its therapeutic potential in PH. Methods: Male C57BL/6J mice were injected with SU5416 weekly during 3 weeks of exposure to 10% oxygen to cause PH. We first tested the effects of adeno-associated virus 9 (AAV9) delivery which was specifically designed to block miR-495 in the lungs of the PH model. Then, the biological function of miR-495 was analyzed in cultured pulmonary arterial endothelial cells (PAECs) under hypoxic condition. Results: The inhibition of miR-495 improves hemodynamics and vascular remodeling in PH. At the same time, these effects were associated with increases in angiogenic transcription factor VEZF1 and marked upregulation of other angiogenic genes such as Angpt-1 and IGF1. In vitro, cultured mouse PAECs were transfected with miR-495 inhibitor or miR-495 mimics. Both the flow cytometry results and CCK8 assay showed that miR-495 inhibitor increased the percentage of cells in the G2/M+S phase, and the wound healing assays indicated that the migration capacity of PAECs transfected with miR-495 inhibitor was increased compared to the inhibitor-NC cells. Conclusions: Our results indicate that AAV9-TuD-miR-495 delivery improves hemodynamic and pulmonary vascular structural changes in PH mice.
References
1.
Rabinovitch
M
. Pathobiology of pulmonary hypertension
. Annu Rev Pathol
. 2007
;2
(1
):369
–99
.
[PubMed]
1553-40062.
Rabinovitch
M
. Molecular pathogenesis of pulmonary arterial hypertension
. J Clin Invest
. 2008
Jul
;118
(7
):2372
–9
.
[PubMed]
0021-97383.
Tuder
RM
, Chacon
M
, Alger
L
, Wang
J
, Taraseviciene-Stewart
L
, Kasahara
Y
, et al. Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis
. J Pathol
. 2001
Oct
;195
(3
):367
–74
.
[PubMed]
0022-34174.
Campbell
AI
, Zhao
Y
, Sandhu
R
, Stewart
DJ
. Cell-based gene transfer of vascular endothelial growth factor attenuates monocrotaline-induced pulmonary hypertension
. Circulation
. 2001
Oct
;104
(18
):2242
–8
.
[PubMed]
0009-73225.
Partovian
C
, Adnot
S
, Raffestin
B
, Louzier
V
, Levame
M
, Mavier
IM
, et al. Adenovirus-mediated lung vascular endothelial growth factor overexpression protects against hypoxic pulmonary hypertension in rats
. Am J Respir Cell Mol Biol
. 2000
Dec
;23
(6
):762
–71
.
[PubMed]
1044-15496.
Zhao
YD
, Campbell
AI
, Robb
M
, Ng
D
, Stewart
DJ
. Protective role of angiopoietin-1 in experimental pulmonary hypertension
. Circ Res
. 2003
May
;92
(9
):984
–91
.
[PubMed]
0009-73307.
Nadeau
V
, Potus
F
, Boucherat
O
, Paradis
R
, Tremblay
E
, Iglarz
M
, et al. Dual ETA/ETB blockade with macitentan improves both vascular remodeling and angiogenesis in pulmonary arterial hypertension
. Pulm Circ
. 2018
Jan-Mar
;8
(1
):2045893217741429
.
[PubMed]
2045-89328.
Jin
RC
, Min
PK
, Chan
SY
. Microrna in the diseased pulmonary vasculature: implications for the basic scientist and clinician
. J Korean Soc Hypertens
. 2013
Mar
;19
(1
):1
–16
.
[PubMed]
2233-81369.
Welten
SM
, Goossens
EA
, Quax
PH
, Nossent
AY
. The multifactorial nature of microRNAs in vascular remodelling
. Cardiovasc Res
. 2016
May
;110
(1
):6
–22
.
[PubMed]
0008-636310.
Grant
JS
, White
K
, MacLean
MR
, Baker
AH
. MicroRNAs in pulmonary arterial remodeling
. Cell Mol Life Sci
. 2013
Dec
;70
(23
):4479
–94
.
[PubMed]
1420-682X11.
Liang
J
, Huang
W
, Cai
W
, Wang
L
, Guo
L
, Paul
C
, et al. Inhibition of microrna-495 enhances therapeutic angiogenesis of human induced pluripotent stem cells
. Stem Cells
. 2017
Feb
;35
(2
):337
–50
.
[PubMed]
1066-509912.
Welten
SM
, Bastiaansen
AJ
, de Jong
RC
, de Vries
MR
, Peters
EA
, Boonstra
MC
, et al. Inhibition of 14q32 MicroRNAs miR-329, miR-487b, miR-494, and miR-495 increases neovascularization and blood flow recovery after ischemia
. Circ Res
. 2014
Sep
;115
(8
):696
–708
.
[PubMed]
0009-733013.
Pullamsetti
SS
, Doebele
C
, Fischer
A
, Savai
R
, Kojonazarov
B
, Dahal
BK
, et al. Inhibition of microRNA-17 improves lung and heart function in experimental pulmonary hypertension
. Am J Respir Crit Care Med
. 2012
Feb
;185
(4
):409
–19
.
[PubMed]
1073-449X14.
Welten
SM
, de Jong
RC
, Wezel
A
, de Vries
MR
, Boonstra
MC
, Parma
L
, et al. Inhibition of 14q32 microRNA miR-495 reduces lesion formation, intimal hyperplasia and plasma cholesterol levels in experimental restenosis
. Atherosclerosis
. 2017
Jun
;261
:26
–36
.
[PubMed]
0021-915015.
Ueda
T
, Volinia
S
, Okumura
H
, Shimizu
M
, Taccioli
C
, Rossi
S
, et al. Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis
. Lancet Oncol
. 2010
Feb
;11
(2
):136
–46
.
[PubMed]
1470-204516.
Guo
L
, Liu
Y
, Bai
Y
, Sun
Y
, Xiao
F
, Guo
Y
. Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis
. Eur J Cancer
. 2010
Jun
;46
(9
):1692
–702
.
[PubMed]
0959-804917.
Hwang-Verslues
WW
, Chang
PH
, Wei
PC
, Yang
CY
, Huang
CK
, Kuo
WH
, et al. miR-495 is upregulated by E12/E47 in breast cancer stem cells, and promotes oncogenesis and hypoxia resistance via downregulation of E-cadherin and REDD1
. Oncogene
. 2011
May
;30
(21
):2463
–74
.
[PubMed]
0950-923218.
Sun
Z
, Nie
X
, Sun
S
, Dong
S
, Yuan
C
, Li
Y
, Xiao
B
, Jie
D
, Liu
Y
: Long non-coding rna meg3 downregulation triggers human pulmonary artery smooth muscle cell proliferation and migration via the p53 signaling pathway.
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 2017
;42:2569-2581. 19.
Aitsebaomo
J
, Kingsley-Kallesen
ML
, Wu
Y
, Quertermous
T
, Patterson
C
. Vezf1/DB1 is an endothelial cell-specific transcription factor that regulates expression of the endothelin-1 promoter
. J Biol Chem
. 2001
Oct
;276
(42
):39197
–205
.
[PubMed]
0021-925820.
Jurasz
P
, Courtman
D
, Babaie
S
, Stewart
DJ
. Role of apoptosis in pulmonary hypertension: from experimental models to clinical trials
. Pharmacol Ther
. 2010
Apr
;126
(1
):1
–8
.
[PubMed]
0163-725821.
Bauer
EM
, Shapiro
R
, Billiar
TR
, Bauer
PM
. High mobility group Box 1 inhibits human pulmonary artery endothelial cell migration via a Toll-like receptor 4- and interferon response factor 3-dependent mechanism(s)
. J Biol Chem
. 2013
Jan
;288
(2
):1365
–73
.
[PubMed]
0021-925822.
Zhao
YD
, Courtman
DW
, Ng
DS
, Robb
MJ
, Deng
YP
, Trogadis
J
, et al. Microvascular regeneration in established pulmonary hypertension by angiogenic gene transfer
. Am J Respir Cell Mol Biol
. 2006
Aug
;35
(2
):182
–9
.
[PubMed]
1044-154923.
Baber
SR
, Deng
W
, Master
RG
, Bunnell
BA
, Taylor
BK
, Murthy
SN
, et al. Intratracheal mesenchymal stem cell administration attenuates monocrotaline-induced pulmonary hypertension and endothelial dysfunction
. Am J Physiol Heart Circ Physiol
. 2007
Feb
;292
(2
):H1120
–8
.
[PubMed]
0363-613524.
Stewart
DJ
, Mei
SH
. Cell-based therapies for lung vascular diseases: lessons for the future
. Proc Am Thorac Soc
. 2011
Nov
;8
(6
):535
–40
.
[PubMed]
1546-322225.
Khan
IF
, Hirata
RK
, Russell
DW
. AAV-mediated gene targeting methods for human cells
. Nat Protoc
. 2011
Apr
;6
(4
):482
–501
.
[PubMed]
1754-218926.
Xiao
X
, Guo
P
, Prasadan
K
, Shiota
C
, Peirish
L
, Fischbach
S
, et al. Pancreatic cell tracing, lineage tagging and targeted genetic manipulations in multiple cell types using pancreatic ductal infusion of adeno-associated viral vectors and/or cell-tagging dyes
. Nat Protoc
. 2014
Dec
;9
(12
):2719
–24
.
[PubMed]
1754-218927.
Clark
AL
, Maruyama
S
, Sano
S
, Accorsi
A
, Girgenrath
M
, Walsh
K
, et al. Mir-410 and mir-495 are dynamically regulated in diverse cardiomyopathies and their inhibition attenuates pathological hypertrophy
. PLoS One
. 2016
Mar
;11
(3
):e0151515
.
[PubMed]
1932-620328.
Fu
J
, Chen
Y
, Li
F
. Attenuation of microrna-495 derepressed pten to effectively protect rat cardiomyocytes from hypertrophy
. Cardiology
. 2018
;139
(4
):245
–54
.
[PubMed]
0008-6312© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
